Cancer Treatment-Induced Bone Loss in Hormone-Sensitive Cancer: The Paradigm of Cancer Survivor Bone Health Management.

2区医学 Q2 Medicine Frontiers of Hormone Research Pub Date : 2021-01-01 Epub Date: 2021-05-04 DOI:10.1159/000514692

Nicoletta Fortunati, Filippo Gatti, Francesco Felicetti, Enrico Brignardello

引用次数: 0

Abstract

Cancer therapy-induced bone loss (CTIBL), occurring especially in hormone-treated breast and prostate cancer patients, is a noteworthy long-term consequence of cancer treatments. Because of its negative impact on the quality life of cancer survivors, it deserves much attention. We here summarize the pathophysiology of CTIBL in breast and prostate cancer, its clinical presentation, management, and treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

激素敏感癌症治疗诱导的骨质流失:癌症幸存者骨健康管理的范例。

癌症治疗引起的骨质流失(CTIBL)，特别是发生在激素治疗的乳腺癌和前列腺癌患者中，是癌症治疗的一个值得注意的长期后果。由于其对癌症幸存者生活质量的负面影响，值得引起人们的重视。我们在此总结CTIBL在乳腺癌和前列腺癌中的病理生理、临床表现、管理和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.